Ripretinib

02/21

ALTERNATE NAMES: N-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3- yl]-2-fluorophenyl}-N'-phenylurea; DCC-2618; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea

CATALOG #:
B3106-1 1 mg
B3106-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{24}H_{21}BrFN_5O_2$

MOLECULAR WEIGHT: 510.4

CAS NUMBER: 1442472-39-0

APPEARANCE: White to off-white powder

PURITY: ≥ 98%

SOLUBILITY: ~30 mg/ml in DMSO (may need ultrasonication)

DESCRIPTION: Ripretinib is an inhibitor of receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA). *In vitro* kinase inhibition studies show that ripretinib inhibits wild-type KIT and PDGFRA with IC_{50} values of 3 and 3.6 nM. It is approved for the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with 3 kinase inhibitors.

STORAGE TEMPERATURE: -20 ºC

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Dhillon, S. Ripretinib: First Approval. Drugs 80(11):1133-1138 (2020).
2. Smith, B.D., Kaufman, M.D., Lu, W-P., et al. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 2019 35(5):738-751 (2019).

RELATED PRODUCTS:

Icotinib (Cat. No. B3003)
Allitinib (Cat. No. B3002)
DiscoveryPak™ EGFR Tyrosine Kinase Inhibitor Set (Cat. No. K858)
BIBW2992 (Tovok) (Cat. No. 1616)
Avitinib (Cat. No. B2995)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***